All Episodes – Page 5
Browse our complete library of interviews and discussions with leading experts in oncology.
Domenica Lorusso MD PhD: Adding Early PD-1 Checkpoint Inhibition brings Big Reduction of Deaths for Patients with Newly Diagnosed Locally Advanced High-Risk Cervix Cancer
Domenica Lorusso MD PhD: Initial therapy with Pembrolizumab added to chemoradiotherapy boosts survival in high-risk locally advanced cervix cancer
James Larkin FRCP, PhD: CheckMate 067 Study 10-Year Data Show Advanced Melanoma Landscape Transformed by Combo Checkpoint Inhibitor Therapy
James Larkin FRCP, PhD talks about the big changes in survival prospects for patients with advanced and metastatic melanoma that have take place over the last 10 years thanks to combination checkpoint
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting
Bart Neyns MD PhD: Patients with Recurrent Glioblastoma Lived Markedly Longer in Phase 1 Study of Intracranial Autologous Myeloid Dendritic Cell Therapy
bart-neyns-md-phd-injectng-cells-into-cranial-cavity-for-recurrent-glioblastoma-long-survival
Victor Velculescu MD PhD: Ovarian Cancer Noninvasive Detection by Circulating DNA Fragmentome and Protein Biomarker AI Analysis
Victor E Velculescu MD PhD
Timothy Yap MD PhD MBBS: Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency
Timothy Yap MD PhD MBBS selective PARP inhibitor promise in breast, ovarian, pancreatic, prostate tumors.
Stacey Kenfield ScD and June Chan ScD: Prostate Cancer Management: New Evidence of Big Benefit from Exercise:
Stacey Kenfield and June Chan UCSF
Jonathan T. Yang MD PhD: Radiosensitizer Shows Early Clinical Promise to Support Glioblastoma Radiotherapy
Jonathan T Yang, MD, PhD
Heather McArthur MD MPH: Adjuvant Checkpoint Inhibition: Did Not Improve Survival in Patients with Triple-Negative Breast Cancer
Heather McArthur MD MPH
Stefan Paepke MD: An End to “Jumping Breasts” with Mesh Supported Pre-Pectoral Breast Implants
Stefan Paepke MD
Sophie Bosma MD PhD:“Young Boost” Trial Finds Low-Dose Radiation Boost Optimal for Young Patients with High-Risk Early Breast Cancer
Sophie Bosma MD PhD
Adri Voogd PhD: Ductal Carcinoma in Situ: Good Outcomes from Breast Conserving Therapy, but Benefits, Risks, Costs Still Need to be Optimized
Adri Voogd PhD
Annemiek van Hemert MD PhD: “Breast Cancer: MARI Node Marker Helps Most Patients with Extensive Nodal Disease Safely Avoid Axillary Lymph Node Dissection”
Annemiek van Hemert MD PhD
Tim Rattay MBChB PhD: Artificial Intelligence Tool Minimizes Arm Lymphedema After Breast Cancer Surgery and Radiotherapy
Tim Rattay MBChB PhD
Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy
Partial breast irradiation, given before breast-conserving surgery, achieved durable pathologic complete remissions in low-risk breast cancer, and even held out the prospect of surgery-free treatment
Neo-Adjuvant Pembrolizumab Improved Outcomes with High-Risk ER+ HER2- Early Breast Cancer
Heather McArthur MD MPH
Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab
ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC
Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer
Patient Derived Organoids Shine a Light on Epigenetic Archetypes as Key Drivers of Cancer Drug Resistance LONDON, UK—How to stay ahead with treatment as cancer cells evolve to evade therapies and regi
Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer
Homologous Repair Deficient Triple Negative Breast Cancer Positive for BRCA1/2 Mutations Better with Neoadjuvant Olaparib + Carboplatin